Market capitalization | GBP4.03b |
Enterprise Value | GBP4.84b |
P/E (TTM) P/E ratio | 17.82 |
EV/FCF (TTM) EV/FCF | 17.12 |
EV/Sales (TTM) EV/Sales | 2.02 |
P/S ratio (TTM) P/S ratio | 1.68 |
P/B ratio (TTM) P/B ratio | 2.23 |
Dividend yield | 3.46% |
Last dividend (FY23) | GBP0.62 |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
11 Analysts have issued a Hikma Pharmaceuticals forecast:
11 Analysts have issued a Hikma Pharmaceuticals forecast:
Jun '24 |
+/-
%
|
||
Revenue | 2,396 2,396 |
6%
6%
|
|
Gross Profit | 1,063 1,063 |
0%
0%
|
|
EBITDA | 545 545 |
17%
17%
|
EBIT (Operating Income) EBIT | 393 393 |
21%
21%
|
Net Profit | 226 226 |
90%
90%
|
In millions GBP.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. It operates through the following segments: Branded, Injectables, Generics, and Others. The Branded segment sells branded generics and in-licensed patented products in the Middle East and North Africa. The Injectables segment includes generic injectable products distributed globally and primarily used in hospitals. The Generics segment focuses on oral and other non-injectable generic products, and is sold in the U.S. retail market. The Others segment comprises of Arab Medical Containers Ltd., International Pharmaceutical Research Center Ltd. and the chemicals division of Hikma Pharmaceuticals Ltd. (Jordan). The company was founded by Samih Taleb Darwazah in 1978 and is headquartered in London, the United Kingdom.
Head office | United Kingdom |
CEO | Riad Mishlawi |
Employees | 9,100 |
Founded | 1978 |
Website | www.hikma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.